Kiberd B A, Stadnyk A W
Department of Medicine, Dalhousie University, Halifax, N.S., Canada.
Immunopharmacology. 1995 Aug;30(2):131-7. doi: 10.1016/0162-3109(95)00014-k.
Interleukin 1 beta (IL-1 beta) is a potent inflammatory cytokine and IL-1 beta gene expression is elevated in the kidneys of mice with lupus nephritis. This study was designed to examine whether pharmacological administration of the IL-1 receptor antagonist (IL-1ra) would reduce the inflammation in MRL lpr/lpr mice with lupus nephritis. Human recombinant IL-1ra (RA) or saline (SA) was infused by intraperitoneal osmotic minipumps in 16 week old mice (n = 9, group RA or n = 12, group SA, respectively). Age matched MRL +/+ mice served as normal controls. At the end of 4 weeks of treatment glomerular filtration rates (5.4 +/- 0.4 vs 5.6 +/- 0.4 ml/min/kg BW), proteinuria (6.0 +/- 1.0 vs 5.5 +/- 1.2 micrograms IgG/day) glomerular volumes (571 +/- 30 vs 509 +/- 25 microns3 x 10(3)), mesangial volumes (172 +/- 23 vs 158 +/- 17 microns3 x 10(3)), and cells/glomerulus (519 +/- 51 vs 506 +/- 47) were not significantly different between RA and SA groups respectively. There was also no significant differences in spleen sizes, plasma IgG and anti-dsDNA antibody levels despite achieving levels of IL-1ra of over 0.8 microgram/ml in RA mice. Circulating IL-1 was not detected by bioassay in the plasma of diseased or normal mice. In fact, diseased, saline treated mouse plasma inhibited the cell proliferation assay in the presence of IL-1, and dilution studies showed that the endogenous inhibitors were of high titre. Although IL-1 may play a role in the renal injury of lupus nephritis, pharmacological inhibition with IL-1ra in animals with established injury is without effect.(ABSTRACT TRUNCATED AT 250 WORDS)
